BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139

Benzinga · 2d ago
BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $134 to $139.